RCS - Physiomics PLC - Conference Attendance

PhysiomicsAnnouncement

14/10/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221014:nRSN8433Ca&default-theme=true

RNS Number : 8433C  Physiomics PLC  14 October 2022

14 October 2022

 

Physiomics plc

("Physiomics") or ("the Company")

 

Conference attendance

 

Physiomics to attend BioEurope

 

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict
the effects of treatment regimens for cancer and other therapeutic drugs for
the biopharma industry, is pleased to announce that it is attending the
#BIOEurope conference in person in Leipzig, Germany on 24-26 October 2022.

BIOEurope is one of the world's premier biotech partnering conferences and is
expected to host over 4,000 executives from over 2,200 companies at this
year's event.

Physiomics Head of Business Development, Hayley Close, will be attending the
conference to meet with prospective clients, in particular those with assets
between late discovery and early clinical development. Companies interested in
meeting Physiomics at the conference should reach out to us via the conference
partnering system or email Hayley directly at hclose@physiomics.co.uk
(mailto:hclose@physiomics.co.uk) .

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has
worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZXLFFLBLFFBL